ArticlePloS one2025
Magnetic resonance imaging characteristics and survival outcomes of metaplastic breast carcinoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging and Clinicopathological Features of Squamous Cell Metaplastic Breast Carcinoma: A 22-Case Retrospective Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetaplastic breast carcinoma is a rare type of breast carcinoma, and there are limited data about the magnetic resonance imaging (MRI) findings of metaplastic carcinoma. This study evaluates the MRI characteristics and prognostic outcomes across metaplastic carcinoma subtypes. MATERIALS AND
methodsIn this retrospective cohort study, a total of 29 patients with histologically confirmed metaplastic carcinoma from 2011 to 2019 were enrolled. Clinical, pathological, and follow-up data, focusing on disease-free (DFS) and overall survival (OS), are recorded. Breast MRI findings were analyzed and categorized based on BI-RADS 5th edition.
resultAmong the participants, 19 had squamous carcinoma, 8 had metaplastic carcinoma with mesenchymal differentiation, and 2 had unclassified subtypes. The most common findings were a solitary mass (75.8%), high T2 signal (51.7%), and heterogenous enhancement (65.5%) with a washout kinetic curve (86.2%). The apparent diffusion coefficient (ADC) values in the metaplastic carcinoma with mesenchymal differentiation group were significantly higher (mean 1.83 +/- 0.50 x 10-3 mm2/s) in comparison with the squamous carcinoma group (mean 1.12 +/- 0.21 x 10-3 mm2/s). The cut-off point of the ADC value was 1.53x10-3 mm2/s, with a sensitivity of 71.4% and a specificity of 100% (AUC = 0.937). The five-year DFS and OS rates were 63% and 79% across the board, 78% and 89.5% in the squamous group, and 50% and 53% in the mesenchymal differentiation group, respectively.
conclusionMetaplastic breast carcinoma is a diverse and aggressive malignancy with variable prognosis. Our findings indicate that mesenchymal differentiation is characterized by higher ADC values and correlates with a worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.